S

everal lawmakers are targeting the sky-high price of an old drug that cost just $50 for a bottle of 100 pills a little more than a decade ago but goes for $15,000 today.

The drug, which was once called Daranide and is now known as Keveyis, was originally approved in 1958 to treat glaucoma, although it was more recently approved to combat periodic paralysis and received orphan status. This means the drug was endorsed for a rare disorder affecting a small group of people — about 5,000 in the U.S. — and also several years of market exclusivity.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • One might also observe that here was a ‘local to Boston’ example – Amag Pharmaceuticals of Waltham (MA), which makes Makena. There was another in the St Louis area that I cannot recall where the FDA did step in – who can forget that one, although, sadly, I cannot recall the company name.

    • Ah, think URL (acquired by Takeda?) and Colcrys – after reapproval, the cost delta was an increase to $5/pill …. from $0.09 USD [ or 9 cents]. (Source – Pharmalot, 05 MAY 2015)

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.